Вы искали: myelosuppression (Шведский - Английский)

myelosuppression:
myelosuppression:

tf myelosuppression.
or concomitant administration of neupopeg and 5-fluorouracil (5-fu) or other antimetabolites has been shown to potentiate myelosuppression.

myelosuppression/neutropeni
myelosuppression/neutropenia

kraftig myelosuppression kan ske.
severe myelosuppression may occur.

myelosuppression är därför vanlig.
myelosuppression is thus common.

tabell 1 dosjusteringar för myelosuppression
table 1 dose modifications for myelosuppression

myelosuppression rapporterades ofta i alla patientpopulationer.
myelosuppression was commonly reported in all patient populations.

infektioner och maligniteter som orsakar myelosuppression
infections and malignancies causing myelosuppression

inga tecken på kumulativ myelosuppression observerades.
no evidence of cumulative myelosuppression was observed.

allvarlig myelosuppression (se avsnitt 4.4).
severe myelosuppression (see section 4.4).

den dosbegränsande toxiciteten utgörs vanligtvis av myelosuppression.
myelosuppression is usually the dose-limiting toxicity.

tromboflebit, lungemboli) eller grav myelosuppression. r in
pulmonary embolism) or severe myelosuppression.

infektioner myelosuppression kan leda till neutropeni och ökad infektionsrisk.
infections myelosupression may lead to neutropenia and an increased risk of infection.

Återhämtningen från myelosuppression sker vanligen snabbt när behandlingen avbryts.
recovery from myelosuppression is usually rapid when therapy is discontinued.

de flesta patienterna fortsatte behandlingen utan ytterligare tecken på myelosuppression.
most patients continued treatment without further evidence of myelosuppression.

den oftast rapporterade biverkningen är myelosuppression med neutropeni som vanligaste manifestation.
the most frequently reported adverse reaction is myelosuppression with neutropenia as the most common manifestation.

myelosuppression och immunsuppression var de önskade terapeutiska effekterna av den konditionerande behandlingen.
myelo-suppression and immuno-suppression were the desired therapeutic effects of the conditioning regimen.

oncaspar kan orsaka mild till måttlig myelosuppression, och alla tre blodkroppslinjerna kan påverkas.
oncaspar can cause mild to moderate myelosuppression, and all three blood cell lines can be affected.

1 baserat på laboratorieutvärderingar: maximal grad av myelosuppression (behandlad population)
1 based on laboratory assessments: maximal degree of myelosuppression (treated population)

mycket vanliga: allvarlig neutropeni, allvarlig leukopeni, trombocytopeni, anemi, myelosuppression
very common: severe neutropenia, severe leucopenia, thrombocytopenia, anaemia, myelosuppression